Top

Published in:

2021 | OriginalPaper | Chapter

Cytotoxic Activity of Raphanus sativus Linn. on Selected Cancer Cell Lines and Mechanistic Pathways Predicted Through Mathematical Modeling

Authors : Angelyn Lao, Jan Marie Claire Edra, Kathleen Dane Talag, Daisylyn Senna Tan, Glenn Oyong, Marissa Noel, Ma. Luisa Enriquez, Maria Carmen Tan

Published in: Modelling, Simulation and Applications of Complex Systems

Publisher: Springer Singapore

Activate our intelligent search to find suitable subject content or patents.

search-config

AI-assisted search

Off

Abstract

Studies have shown different effects of Raphanus sativus L. (RS) extract on different cancer cell types. However, the dynamics of gene regulation between RS and cancer is still unknown. In this study, a mathematical model was incorporated to link cell cycle regulation pathways associated with the pharmacognosy of radish extracts towards breast cancer (BC), chronic myelogenous leukemia (CML), and colorectal cancer (CC). The cell cycle regulation pathways considered were MAPK/ERK and PI3K/Akt signaling pathways. A model created using ordinary differential equations was used to simulate the steady state concentrations of the proteins in both pathways, before and after exposure to radish extracts. Among the proteins ubiquitous in these pathways, Cyclin D1-CDK complex and p53 were found to be predominantly dysregulated in most cancers. The expression of these proteins was used as the benchmark of the pharmacognosy of radish extracts. Our simulation showed a decreasing trend in the binding specificities (\(K_M\)) of RS with Cyclin D1-CDK complex and p53 respectively from CML \(\left[ 5\,\upmu \mathrm{M}, 100 \,\upmu \mathrm{M}\right] \), CC \([2.5 \times 10^{-2}\,\upmu \mathrm{M}, 10\,\upmu \mathrm{M}]\) up to BC \([10^{-6}\,\upmu \mathrm{M}, 10^{-3}\,\upmu \mathrm{M}]\) which led to a decrease in Cyclin D1-CDK complex (90.74% for BC, 73.42% for CC, 1.10% for CML) and an increase in p53 (83.47% for BC, 62.75% for CC, 5.69% for CML). This suggests that the anticancer activity of RS was through the moderation of cell proliferation and induction of apoptosis in malignant neoplasms. Hence, the model proposed that RS had high chemotherapeutic activity on BC while having moderate efficacy on CC and insignificant efficacy on CML as substantiated by cytotoxicity assays on MCF-7 and HT-29 which both exhibited \(IC_{50} < 20~\upmu \)g/mL and K562 trials which gave \(IC_{50} > 100\,\upmu \)g/mL.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 390 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Maschinenbau + Werkstoffe

Jetzt Wissensvorsprung sichern!

inform now

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

inform now

previous chapter Control, Sensitivity and Identification of a Cardiovascular-Respiratory System Model

next chapter Bifurcation Analysis of a Tuberculosis Model with the Risk of Re-infection

Abbas, T., Dutta, A.: p21 in cancer: intricate networks and multiple activities. Nature Rev. Cancer 9(6), 400–414 (2009). https://doi.org/10.1038/nrc2657CrossRef

Au, W.Y., et al.: Chronic myeloid leukemia in Asia. Int. J. Hematol. 89(1), 14–23 (2009). https://doi.org/10.1007/s12185-008-0230-0MathSciNetCrossRef

Beevi, S.S., Mangamoori, L.N., Subathra, M., Edula, J.R.: Hexane extract of Raphanus sativus L. roots inhibits cell proliferation and induces apoptosis in human cancer cells by modulating genes related to apoptotic pathway. Plant Foods Hum. Nutr. 65(3), 200–209 (2010). https://doi.org/10.1007/s11130-010-0178-0

Berg, J.M.J.M., Tymoczko, J.L., Stryer, L., Stryer, L.: Biochemistry. W.H. Freeman, New York (2002)

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A.: Global cancer statistics 2018: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018)

Buban, C.E.: Colorectal cancer curable if detected early | Inquirer Business (2013)

Bykov, V.J., Eriksson, S.E., Bianchi, J., Wiman, K.G.: Targeting mutant p53 for efficient cancer therapy. Nat. Rev. Cancer 18(2), 89 (2018)CrossRef

Cragg, G.M., Newman, D.J.: Natural Products as Sources of Antitumor Agents

Crown, J., O’Shaughnessy, J., Gullo, G.: Emerging targeted therapies in triple-negative breast cancer. Ann. Oncol. 23(suppl 6), vi56–vi65 (2012). https://doi.org/10.1093/annonc/mds196

10.

Dang, C.V.: MYC, metabolism, cell growth, and tumorigenesis. Cold Spring Harbor Perspect. Med. 3(8), a014,217 (2013). https://doi.org/10.1101/cshperspect.a014217

11.

Donato, N.J., et al.: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101(2), 690–698 (2003). https://doi.org/10.1182/blood.V101.2.690CrossRef

12.

Druker, B.J., et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344(14), 1031–1037 (2001). https://doi.org/10.1056/NEJM200104053441401CrossRef

13.

Duffy, M.J., Synnott, N.C., McGowan, P.M., Crown, J., O’Connor, D., Gallagher, W.M.: p53 as a target for the treatment of cancer. Cancer Treat. Rev. 40(10), 1153–1160 (2014). https://doi.org/10.1016/j.ctrv.2014.10.004CrossRef

14.

Eckert, L.B., et al.: Involvement of ras activation in human breast cancer cell signaling, invasion, and Anoikis. Cancer Res. 64(13), 4585–4592 (2004). https://doi.org/10.1158/0008-5472.CAN-04-0396CrossRef

15.

Furqan, M., Akinleye, A., Mukhi, N., Mittal, V., Chen, Y., Liu, D.: STAT inhibitors for cancer therapy. J. Hematol. Oncol. 6(1), 90 (2013). https://doi.org/10.1186/1756-8722-6-90CrossRef

16.

Geran, R.I.: Protocols for screening chemical agents and natural products against animal tumors and other biological systems (3rd edn.) Cancer Chemother. Rep. 3, 51–61 (1972)

17.

Goi, T., Yamaguchi, A., Nakagawara1, G., Urano, T., Shiku, H., Furukawa, K.: Reduced expression of deleted colorectal carcinoma (DCC) protein in established colon cancers. Br. J. Cancer 77(3), 466–471 (1998)

18.

Gollob, J.A., Wilhelm, S., Carter, C., Kelley, S.L.: Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin. Oncol. 33(4), 392–406 (2006). https://doi.org/10.1053/j.seminoncol.2006.04.002CrossRef

19.

Gómez-Casares, M.T., et al.: MYC antagonizes the differentiation induced by imatinib in chronic myeloid leukemia cells through downregulation of p27KIP1. Oncogene 32(17), 2239–2246 (2013). https://doi.org/10.1038/onc.2012.246CrossRef

20.

Gong, H., Zuliani, P., Komuravelli, A., Faeder, J.R., Clarke, E.M.: Analysis and verification of the HMGB1 signaling pathway. BMC Bioinform. 11(Suppl 7), S10 (2010). https://doi.org/10.1186/1471-2105-11-S7-S10CrossRef

21.

Jacinto, S.D., Chun, E.A.C., Montuno, A.S., Shen, C.C., Espineli, D.L., Ragasa, C.Y.: Cytotoxic cardenolide and sterols from Calotropis gigantea. Nat. Prod. Commun. 6(6), 803–6 (2011)

22.

John, P.C.L., Mews, M., Moore, R.: Cyclin/CDK complexes: their involvement in cell cycle progression and mitotic division. Protoplasma 216(3–4), 119–142 (2001). https://doi.org/10.1007/BF02673865CrossRef

23.

Johnson, S.M., et al.: Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J. Am. Coll. Surg. 210(5), 767–776 (2010). https://doi.org/10.1016/j.jamcollsurg.2009.12.008CrossRef

24.

Kamran, M.Z., Patil, P., Gude, R.P.: Role of STAT3 in cancer metastasis and translational advances. BioMed Res. Int. 2013 (2013). https://doi.org/10.1155/2013/421821

25.

Kanehisa, M., Furumichi, M., Tanabe, M., Sato, Y., Morishima, K.: KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 45(D1), D353–D361 (2017). https://doi.org/10.1093/nar/gkw1092CrossRef

26.

Kanehisa, M., Goto, S.: KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28(1), 27–30 (2000). https://doi.org/10.1093/nar/28.1.27CrossRef

27.

Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M., Tanabe, M.: KEGG as a reference resource for gene and protein annotation. Nucleic Acids Res. 44(D1), D457–D462 (2016). https://doi.org/10.1093/nar/gkv1070CrossRef

28.

Kanehisa Laboratories: KEGG PATHWAY: Colorectal cancer - Homo sapiens (human)

29.

Kanehisa Laboratories: KEGG PATHWAY: Chronic myeloid leukemia - Homo sapiens (human) (2017)

30.

Kang, H.W., et al.: A mathematical model for microrna in lung cancer. PLoS ONE 8(1), e53,663 (2013). https://doi.org/10.1371/journal.pone.0053663

31.

Kasper, D., Fauci, A., Hauser, S., Longo, D., Jameson, J., Loscalzo, J.: Harrison’s principles of internal medicine, 19e, vol. 1. Mcgraw-Hill (2015)

32.

Kaymaz, B.T., et al.: Repression of STAT3, STAT5A, and STAT5B expressions in chronic myelogenous leukemia cell line K-562 with unmodified or chemically modified siRNAs and induction of apoptosis. Ann. Hematol. 92(2), 151–162 (2013). https://doi.org/10.1007/s00277-012-1575-2CrossRef

33.

Kim, J.K., Diehl, J.A.: Nuclear cyclin D1: an oncogenic driver in human cancer. J. Cell. Physiol. 220(2), 292–296 (2009). https://doi.org/10.1002/jcp.21791CrossRef

34.

Kim, W.K., et al.: Radish (Raphanus sativus L. leaf) ethanol extract inhibits protein and mRNA expression of ErbB(2) and ErbB(3) in MDA-MB-231 human breast cancer cells. Nutr. Res. Pract. 5(4), 288–93 (2011). https://doi.org/10.4162/nrp.2011.5.4.288

35.

Koh, G., Teong, H.F.C., Clement, M.V., Hsu, D., Thiagarajan, P.: A decompositional approach to parameter estimation in pathway modeling: a case study of the Akt and MAPK pathways and their crosstalk. Bioinformatics 22(14), e271–e280 (2006). https://doi.org/10.1093/bioinformatics/btl264CrossRef

36.

Krimpenfort, P., Song, J.Y., Proost, N., Zevenhoven, J., Jonkers, J., Berns, A.: Deleted in colorectal carcinoma suppresses metastasis in p53-deficient mammary tumours. Nature 482(7386), 538–541 (2012). https://doi.org/10.1038/nature10790CrossRef

37.

Lane, D.P., Cheok, C.F., Lain, S.: p53-based cancer therapy. Cold Spring Harbor Perspect. Biol. 2(9), a001,222 (2010). https://doi.org/10.1101/cshperspect.a001222

38.

Li, C., et al.: PD-0332991 induces G1 arrest of colorectal carcinoma cells through inhibition of the cyclin-dependent kinase-6 and retinoblastoma protein axis. Oncol. Lett. 7(5), 1673–1678 (2014). https://doi.org/10.3892/ol.2014.1957CrossRef

39.

Li, Y., Chinni, S.R., Sarkar, F.H.: Selective growth regulatory and pro-apoptotic effects of DIM is mediated by AKT and NF-kappaB pathways in prostate cancer cells. Front Biosci 10, 236–43 (2005)CrossRef

40.

Mayer, I.A., Arteaga, C.L.: PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor-positive breast cancer? J. Clin. Oncol. 32(27), 2932–2934 (2014). https://doi.org/10.1200/JCO.2014.55.9591CrossRef

41.

McCain, J.: The MAPK (ERK) pathway: investigational combinations for the treatment of BRAF-mutated metastatic melanoma. P T Peer-Review. J. Formulary Manage. 38(2), 96–108 (2013)MathSciNet

42.

Mehlen, P., Rabizadeh, S., Snipas, S.J., Assa-Munt, N., Salvesen, G.S., Bredesen, D.E.: The DCC gene product induces apoptosis by a mechanism requiring receptor proteolysis. Nature 395(6704), 801–804 (1998). https://doi.org/10.1038/27441CrossRef

43.

Moreno-Bueno, G., et al.: Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene 22(38), 6115–6118 (2003). https://doi.org/10.1038/sj.onc.1206868CrossRef

44.

Morse, M.A., Stoner, G.D.: Cancer chemoprevention: principles and prospects. Carcinogenesis 14(9), 1737–1746 (1993)CrossRef

45.

Muller, P.A.J., Vousden, K.H.: Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25(3), 304–17 (2014). https://doi.org/10.1016/j.ccr.2014.01.021CrossRef

46.

Ngelangel, C.A., Wang, E.H.M.: Cancer and the Philippine cancer control program. Jpn. J. Clin. Oncol. 32, 52–61 (2002)CrossRef

47.

Ngoma, T.: World health organization cancer priorities in developing countries. Ann. Oncol. 17, viii9–viii14 (2006)

48.

Nilsson, J.A., Cleveland, J.L.: Myc pathways provoking cell suicide and cancer. Oncogene 22(56), 9007–9021 (2003). https://doi.org/10.1038/sj.onc.1207261CrossRef

49.

Peltomäki, P.: Deficient DNA mismatch repair: a common etiologic factor for colon cancer. Hum. Mol. Genet. 10(7), 735–40 (2001)CrossRef

50.

Polak, R., Buitenhuis, M.: The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. Blood 119(4), 911–23 (2012). https://doi.org/10.1182/blood-2011-07-366203CrossRef

51.

Pópulo, H., Lopes, J.M., Soares, P.: The mTOR signalling pathway in human cancer. Int. J. Mol. Sci. 13(2), 1886–1918 (2012). https://doi.org/10.3390/ijms13021886CrossRef

52.

Prakash, D., Sharma, G. (eds.): Phytochemicals of nutraceutical importance. CABI, Wallingford (2014). https://doi.org/10.1079/9781780643632.0000

53.

Roberts, P.J., Der, C.J.: Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26(22), 3291–3310 (2007). https://doi.org/10.1038/sj.onc.1210422CrossRef

54.

Rochlitz, C.F., Herrmann, R., de Kant, E.: Overexpression and amplification of c-myc during progression of human colorectal cancer. Oncology 53(6), 448–54 (1996). https://doi.org/10.1159/000227619CrossRef

55.

Rosen, L.S., Ashurst, H.L., Chap, L.: Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review. Oncologist 15(3), 216–35 (2010). https://doi.org/10.1634/theoncologist.2009-0145CrossRef

56.

Rottenberg, S., Jonkers, J.: MEK inhibition as a strategy for targeting residual breast cancer cells with low DUSP4 expression. Breast Cancer Res. 14(6), 324 (2012). https://doi.org/10.1186/bcr3327CrossRef

57.

Saini, K.S., et al.: Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. Cancer Treat. Rev. 39(8), 935–46 (2013). https://doi.org/10.1016/j.ctrv.2013.03.009CrossRef

58.

Srinivasan, D., Plattner, R.: Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Can. Res. 66(11), 5648–5655 (2006). https://doi.org/10.1158/0008-5472.CAN-06-0734CrossRef

59.

Srinivasan, D., Sims, J.T., Plattner, R.: Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 27(8), 1095–1105 (2008). https://doi.org/10.1038/sj.onc.1210714CrossRef

60.

Steelman, L.S., et al.: Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 3(3), 192–222 (2011). https://doi.org/10.18632/aging.100296CrossRef

61.

Tan, M.C.S., Enriquez, M.L.D., Arcilla, R.G., Noel, M.G.: Determining the apoptotic-inducing property of isothiocyanates extracted from three cultivars of Raphanus sativus Linn. Using the comet assay. J. Appl. Pharm. Sci. 7(9), 44–51 (2017). https://doi.org/10.7324/JAPS.2017.70906

62.

Tsygvintsev, A., Marino, S., Kirschner, D.E.: A mathematical model of gene therapy for the treatment of cancer. In: Mathematical Methods and Models in Biomedicine, pp. 367–385. Springer (2013)

63.

Tubeza, P.C.: Breast cancer is the most prevalent in PH — Inquirer News (2012)

64.

Wang, Y., et al.: Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression. Cancer Discov. 3(3), 294–307 (2013). https://doi.org/10.1158/2159-8290.CD-12-0198CrossRef

65.

Wee, K.B., Aguda, B.D.: Akt versus p53 in a network of oncogenes and tumor suppressor genes regulating cell survival and death. Biophys. J. 91(3), 857–865 (2006). https://doi.org/10.1529/BIOPHYSJ.105.077693CrossRef

66.

WHO — early diagnosis and screening (2017)

67.

Xiong, A., Yang, Z., Shen, Y., Zhou, J., Shen, Q.: Transcription factor STAT3 as a novel molecular target for cancer prevention. Cancers 6(2), 926–957 (2014). https://doi.org/10.3390/cancers6020926CrossRef

Title: Cytotoxic Activity of Raphanus sativus Linn. on Selected Cancer Cell Lines and Mechanistic Pathways Predicted Through Mathematical Modeling
Authors: Angelyn Lao
Jan Marie Claire Edra
Kathleen Dane Talag
Daisylyn Senna Tan
Glenn Oyong
Marissa Noel
Ma. Luisa Enriquez
Maria Carmen Tan
Publisher: Springer Singapore
Book: Modelling, Simulation and Applications of Complex Systems
Print ISBN: 978-981-16-2628-9

Electronic ISBN: 978-981-16-2629-6

Copyright Year: 2021
DOI: https://doi.org/10.1007/978-981-16-2629-6_9

Springer Professional

Abstract

Please log in to get access to your license.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Technik"

Springer Professional "Wirtschaft"

Premium Partner